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Characterization of the human topoisomerase IIb (TOP2B) promoter
activity : essential roles of the nuclear factor-Y (NF-Y)- and specificity
protein-1 (Sp1)-binding sites
Chun-Nam LOK, Alexander J. LANG, Shelagh E. L. MIRSKI and Susan P. C. COLE1
Cancer Research Laboratories and Department of Pharmacology & Toxicology, Queen’s University, Kingston, Ontario, Canada K7L 3N6
Eukaryotic topoisomerase II (topo II) catalyses topological
genomic changes essential for chromosome segregation, chroma-
tin reorganization, DNA replication and transcription. Mam-
malian topo II exists as two isoforms, designated a and b.
Human topo IIa is an important cancer drug target, and an es-
tablished determinant of drug sensitivity and resistance. Human
topo IIb is also the target of anticancer drugs but its role in
drug resistance is less clear. The two human topo II proteins are
encoded by the TOP2A and TOP2B genes, respectively, which
despite their highly conserved structural organization, are subject
to distinctly different modes of regulation. In the present study,
we have cloned and characterized the human TOP2B promoter
containing a 1.3 kb fragment of the 5«-flanking and untranslated
region (fi1067 to ›193). We found that the promoter activity of
this TOP2B fragment was constant throughout the cell cycle, in
contrast to the activity of the proximal promoter of TOP2A
which was low in resting cells and enhanced during proliferation.
INTRODUCTION
DNA topoisomerase II (topo II ; human gene symbol TOP2) is
a nuclear enzyme that alters the topology of DNA. It is essential
for a number of nuclear processes, including chromosome
condensation, chromatid separation and relief of torsional stress
that occurs during DNA replication and transcription (reviewed
in [1]). Two isoforms of the mammalian enzyme exist, designated
topo IIa and topo IIb, that are encoded by the TOP2A and
TOP2B genes located on chromosomes 17q21–22 and 3p24,
respectively [2–4]. The high degree of sequence similarity and
conservation of the intron}exon organization of the two genes
indicates that they have most likely arisen by duplication of an
ancestral gene [5]. The two isoforms share similar catalytic
properties [6], but the regulation of their activities and patterns
of expression in normal tissues are distinctly different. For
example, topo IIa expression is tightly regulated in a cell-cycle-
and proliferation-dependent manner [7,8], and is believed to play
a critical role in mitosis [8,9]. In contrast, topo IIb expression is
relatively independent of growth status and the cell cycle [7,10]
and its cellular function is less certain. In io, topo IIa is
expressed predominantly in proliferating compartments of tissues
whereas topo IIb is more widely expressed in both proliferating
and differentiated tissues [11,12]. Although cell lines lacking topo
IIb expression can be established [13–15], mice with targeted
disruption of TOP2B fail to develop appropriate neural inner-
vation of skeletal muscle and die shortly after birth due to a
Abbreviations used: DOTAP/DOPE, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulphate/dioleoyl phosphatidylethanolamine;
GMSA, gel mobility-shift assay ; ICB, inverted CCAAT box; NF-Y, nuclear factor-Y; Sp1, specificity protein-1 ; SV, simian virus ; topo II, topoisomer-
ase II.
1 To whom correspondence should be addressed (e-mail coles!post.queensu.ca).
Analyses of 5«-serially and internally deleted luciferase reporter
constructs revealed that 80% of the TOP2B promoter activity
could be attributed to the region between fi533 and fi481.
Mutational analyses of putative regulatory elements indicated
that two inverted CCAAT boxes (ICBs) within this region were
essential for TOP2B promoter activity and gel mobility-shift
assays indicated these sites bound the transcription factor nuclear
factor-Y (NF-Y). Co-transfection experiments using a dominant-
negative form of subunit A of NF-Y suggested that TOP2B
promoter activity required direct interaction of NF-Y with the
ICBs. In addition, a specificity protein-1 (Sp1)-binding GC box
located just upstream of the ICBs was shown to contribute to
TOP2B promoter activity in a synergistic manner with the ICBs.
Our results suggest that the binding sites for NF-Y and Sp1 are
critical for TOP2B transcription.
Key words: gene regulation, promoter analysis.
breathing impairment, suggesting that this isoform is essential
for mammalian neural development [16].
Topo IIa is a well-characterized determinant of drug sensitivity
[17,18] and is known to be the cellular target for several widely
used anticancer drugs whose mechanism of action involves either
inhibition of the enzyme’s catalytic activities or stabilization of
topo II–DNA cleavable complexes that leads to DNA damage
[17]. Unfortunately, resistance often emerges after exposure of
tumour cells to topo II-targeting drugs or is inherently present
depending on the type of tumour. Mechanisms of drug resistance
involving topo IIa include altered enzyme activity, aberrant
localization of the enzyme to the nucleus and reduced levels of
protein expression, all of which result in decreased DNA damage
in tumour cells exposed to topo II-targeting drugs [15,18–20].
Numerous studies of the regulatory mechanisms governing
TOP2A gene expression have provided insight as to how this
gene may be down-regulated in drug resistance as well as
furthering our understanding of the biological function(s) of this
isoenzyme [18,21].
Topo IIb is also known to be a drug target, and several
selective inhibitors have been described [22]. Moreover, there is
some evidence that reduced topo IIb expression is associated
with the development of drug resistance [13,14,22,23]. How-
ever, in contrast to topo IIa, little is known about the regu-
latory mechanisms governing expression of this enzyme. As an
initial step towards understanding the factors controlling the ex-
pression of TOP2B, we have isolated a 1.3 kb genomic fragment
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corresponding to the 5«-flanking and untranslated regions of
TOP2B and investigated some of the functional elements and
transcription factors involved in the ability of this region to
drive expression of a reporter gene in transfected cells. Our data
indicate that two inverted CCAAT boxes (ICBs), which bind the
nuclear factor-Y (NF-Y) transcription factor, and a GC box,
which binds the specificity protein-1 (Sp1) transcription factor,
are important for TOP2B promoter activity.
MATERIALS AND METHODS
Cell culture and reagents
HeLa cells and NIH3T3 cells were cultured in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum. Mono-
clonal antibodies against NF-YA (sc-7712) and polyclonal
antiserum against Sp1 (sc-59) were products of Santa Cruz
Biotechnology (Santa Cruz, CA, U.S.A.). Wild-type NF-YA
and dominant-negative mutant NF-YA cDNA expression
vectors were kindly provided by Dr Roberto Mantovani (Uni-
versity of Modenae Reggio, Milano, Italy). Oligonucleotides
were synthesized by Cortec (Kingston, Ontario, Canada) or by
ACGT Corporation (Toronto, Ontario, Canada).
Cloning of the 5«-flanking and untranslated regions of TOP2B and
construction of reporter plasmids
TOP2B genomic clones (109D5 and 263H17) were isolated by
screening a human BAC library using a probe derived from
TOP2B cDNA (›72 to ›1370 of the coding sequence) by the
Canadian Institutes of Health Research Genome Research
Facility (Hospital for Sick Children, Toronto, Ontario, Canada).
Positive clones were digested with HindIII and subcloned into
the pcDNA3.1(fi)2 vector (Promega, Madison, WI, U.S.A.) to
create pcDNA3.1(fi)-TOP2B. The resulting clones were further
screened with a $#P-labelled oligonucleotide probe derived from
TOP2B exon 1 (5«-CCGGGGACCAGCCACTTACCACCC-
AGG-3«) using standard filter-hybridization techniques [24]. One
of the positive clones isolated contained a 4.3 kb fragment that
was determined to include a 1.3 kb sequence upstream of the
translation-initiation site. A 1.4 kb HindIII}EcoRI fragment
from this clone containing the entire 5«-flanking sequence, the
first exon and part of the first intron of TOP2B was inserted into
pGEM3Z2 (Promega) to create pGEM3Z-TOP2B for further
subcloning purposes.
The TOP2B luciferase reporter plasmids were constructed by
subcloning the TOP2B sequence fi1067 to ›193 (where ›1
denotes the major transcription start site) [25] from
pcDNA3.1(fi)-TOP2B into the HindIII}NcoI sites of the pGL3-
Basic luciferase vector (Promega) to create fi1067TOP2B-
pGL3. Various 5«-serially deleted TOP2B luciferase constructs
(see Figure 1 and Figure 3A below) were prepared by standard
PCR cloning techniques. PCR-amplified products spanning pro-
gressively shorter regions of TOP2B promoter and all ending at
›193 were prepared using the appropriate KpnI-tagged forward
primers with the NcoI-containing reverse primer (›193; 5«-
TGGCGTCTTCCATGGCGAGTGCCTCC-3« ; NcoI site in
italics) and fi1067TOP2B-pGL3 as template. The resulting
amplified fragments were then subcloned into the KpnI and NcoI
sites of pGL3-Basic. Additional luciferase constructs with 5«-
ends at positions fi385, fi125 and fi37 were prepared by
restriction-enzyme digestion of the fi1067TOP2B-pGL3 con-
struct and subsequent re-ligation of blunt-ended DNA as follows:
fi385TOP2B-pGL3, HindIII}BstEII; fi125TOP2B-pGL3,
HindIII}PstI ; and fi37TOP2B-pGL3, HindIII}XmaI.
The internally deleted constructs D1-TOP2B, D2-TOP2B and
D3-TOP2B (see Figure 3C below) were prepared by first removing
the BbsI}PpuMI, PpuMI}NotI and NotI}BstEII fragments,
respectively, from pGEM3Z-TOP2B by restriction digestion
followedby recircularization. TheHindIII (fi1067)}NcoI (›193)
fragments from the resulting plasmids were then transferred into
pGL3-Basic. The D4-TOP2B reporter construct was prepared by
subcloning a BstEII-tagged PCR fragment from fi309 to ›193
(NcoI) into a BstEII}NcoI digested vector fragment of
fi1067TOP2B-pGL3. The D5-TOP2B and D6-TOP2B constructs
were prepared by removing PstI-digested or SmaI-digested
fragments, respectively, from fi1067TOP2B-pGL3 followed by
recircularization.
Mutations of several potential regulatory elements (see Fig-
ure 4 below) were introduced into the fi1067TOP2B-pGL3 re-
porter construct by PCR using the oligonucleotides listed in
Table 1. Briefly, two individual amplification reactions were
performed on the wild-type fi1067TOP2B-pGL3 template using
the following primers that have restriction sites introduced
into the mutated elements (Table 1) and primers flanking the
elements fi1067 (5«-CTATCGATAGGTACCAAGCTTTTC-
ATA-3«, HindIII site in italics) and fi385 (5«-GCCGCCA-
CGGTCACCTCCCTCTTGTCC-3«, BstEII site in italics) to
facilitate identification of mutants and subcloning. The two PCR
fragments obtained were digested with the appropriate restriction
enzymes and subcloned into the HindIII and BstEII sites of
fi1067TOP2B-pGL3.
For construction of the TOP2A promoter reporter plasmid
620TOP2A-pGL3, a TOP2A fragment (fi620 to ›90) was
isolated from genomic DNA from human peripheral blood
mononuclear cells by PCR using the primer pairs, 5«-GGGG-
TACCTCCAGCCACCGCACACAGCCTA-3« [fi620; tagged
with a KpnI-recognition site (italics)] and 5«-GAAGATCTGGT-
GACGGTCGTGAAGGGGCTCA-3« [›90; tagged with a
BglII-recognition site (italics)]. The resulting amplified fragments
were then subcloned into the KpnI and BglII sites, respectively,
of pGL3-Basic. The fidelity of all constructs was confirmed by
sequencing (Canadian Molecular Research Services, Ottawa,
Ontario, Canada).
Transfections, reporter assays and flow cytometry
HeLa cells were seeded at 1‹10& cells}well in a 24-well plate the
day before transfection with the luciferase reporter plasmids. For
each transfection, a total of 0.3 lg of plasmid DNA was mixed
with 2 lg of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-
ammonium methylsulphate}dioleoyl phosphatidylethanolamine
(DOTAP}DOPE) liposome (Avanti Polar Lipids, Alabaster,
AL, U.S.A.) in 40 ll of serum-free Dulbecco’s modified Eagle’s
medium and incubated at room temperature for 15 min. The
DNA}lipid mixtures were then added to cells in 250 ll of
complete medium. After a 4 h incubation, the transfection
medium was replaced with fresh medium and the cells further
incubated for 20 h. For co-transfection experiments with NF-
YA cDNA expression vectors, 250 ng of TOP2B reporter plasmid
DNA were transfected together with 50 ng of NF-YA cDNA or
empty vector DNA (pSG5; Stratagene, La Jolla, CA, U.S.A.).
Renilla luciferase internal control expression plasmids (10–30 ng
of pRL-TK, pRL-CMV or pRL-SV40; Promega) were also co-
transfected as indicated in the figure legends. Unless otherwise
stated, the activities of pRL internal control plasmids chosen for
particular experiments were not affected by co-transfection or
post-transfection treatment and hence mainly reflect variations
in transfection efficiencies or cell harvesting between samples.
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Table 1 Oligonucleotides used for gel mobility-shift assays and mutagenesis of putative regulatory elements in the TOP2B promoter
Putative regulatory elements are shown in bold. The mutated nucleotides are underlined and the resulting restriction sites used for facilitating subcloning are indicated. Shown are the upper strands
of the oligonucleotides.
Oligonucleotide Sequence Position Restriction site introduced
TOP2B ICB1 5«-ACA AGG CCC GGA TTG GAC AGC ATG GCG-3« fi501 to fi475
TOP2B mICB1 5«-ACA AGG CCC GTC TAG AAC AGC ATG GCG-3« XbaI
TOP2B ICB2 5«-GGA ATT TTG GGA TTG GCC GAG AGG CTG-3« fi533 to fi507
TOP2B mICB2 5«-GGA ATT TTG GAG ATC TCC GAG AGG CTG-3« Bgl II
MHC Y (prototypical CCAAT box) 5«-ATA TTT TTC TGA TTG GCC AAA GAG TAA-3«
TOP2B GC 5«-CTC GGG TCC CGC CCC TCC AGG-3« fi561 to fi541
TOP2B mGC 5«-CTC GGG TCG AGC TCC TCC AGG-3« Sac I
Sp1 (prototypical) 5«-ATT CGA TCG GGG CGG GGC GAG C-3«
Luciferase activities were determined using the Dual-Luciferase2
Reporter Assay System according to the manufacturer’s instruc-
tions (Promega) using a MicroLumat Plus2 microplate lumino-
meter (EG & G Berthold, Bad Wildbad, Germany). Results are
reported as relative luciferase units.
To follow the effect of cell proliferation on TOP2B and
TOP2A promoter activities, NIH3T3 cells were seeded at 1‹10&
cells}well in 24-well plates and cells transfected the following day
with 300 ng of fi620TOP2A-pGL3 or fi1067TOP2B-pGL3
together with 10 ng of pRL-CMV using DOTAP}DOPE lipo-
somes as before. After 24 h, cells were growth-arrested by serum
starvation in medium containing 0.5% serum for 48 h. Cells
were then stimulated to proliferate by replacing the medium with
medium containing 10% serum. At the specified time periods,
cells were harvested and luciferase activities measured as before.
For estimation of cell-cycle distribution, cells were set up in
parallel in 25 cm# tissue-culture flasks, subjected to the same
growth-arrest}re-stimulation treatments and harvested at speci-
fied intervals for nuclear staining with propidium iodide. Samples
were assayed with an EPICS2 ALTRATM flow cytometer (488 nm
excitation wavelength, 595 nm emission wavelength) and the
data analysed with Expo32TM software (Beckman Coulter,
Mississauga, Ontario, Canada).
Gel mobility-shift assays (GMSAs)
Extracts of nuclear proteins were prepared from cells by salt
extraction of isolated nuclei to a final protein concentration of
2 lg}ll as described in [26]. Oligonucleotides were 5«-end-labelled
with [c-$#P]ATP using T4 DNA kinase to a specific activity
of 500–1000 c.p.m.}fmol and annealed with a 2-fold excess of
complementary oligonucleotides. DNA–protein binding re-
actions (20 ll) containing 10 mM Tris}HCl (pH 7.8), 1 mM
EDTA, 0.1 mM dithiothreitol, 5% glycerol, 1 lg of poly(dI-
dC) [poly(dI-dC) and 5–10 lg of nuclear extract protein were
incubated at room temperature for 10 min. $#P-Labelled oligo-
nucleotides (20 fmol) were then added to each reaction for a
further 30 min. For competition or supershift GMSAs, a 100-
fold excess of unlabelled competitor oligonucleotide or 1 lg of
the appropriate antisera were preincubated with the nuclear
extracts for 15 min at room temperature before adding the $#P-
labelled probes. The DNA–protein complexes were resolved on
6% polyacrylamide gels in 0.25‹Tris}borate}EDTA buffer and
then exposed to Kodak X-ray film at fi70 °C.
Immunoblot analysis
Expression levels of wild-type and dominant-negative NF-YA
in transfected HeLa cells were determined by immunoblot
analysis. Transfected cells were washed and whole-cell lysates
prepared in buffer containing 20 mM Hepes, 450 mM NaC1,
0.5 mM EDTA, 25% glycerol and 0.5 mM PMSF. Protein
extracts (10 lg) were resolved by 10% polyacrylamide gel and
transferred to a nylon membrane. Blots were incubated with a
monoclonal antibody against NF-YA and antibody binding
detected with horseradish peroxidase-conjugated goat anti-
mouse secondary antibody, followed by chemiluminescence
detection (Perkin Elmer Life Sciences).
RESULTS
Isolation of the human TOP2B promoter
A genomic TOP2B clone isolated from a human BAC library
was shown to contain 5«-untranslated and flanking regions of
TOP2B extending more than 1.3 kb upstream of the translational
initiation start codon (Figure 1). Sequencing of this 5« region
showed that it bears minimal sequence similarity with the human
TOP2A promoter but, like TOP2A, lacks a TATA box [25,27].
The TOP2B promoter is very GC-rich with a 90% GC content
in the proximal promoter and 5«-untranslated region. This region
also has a high number of clustered CpG or GpC dinucleotides
with features characteristic of a CpG island. In addition, two
short dinucleotide repeats, (GT)
&
at fi420 and (GT)
’
at fi338,
and one short trinucleotide repeat, (GGC)
’
at fi377, were
identified. The entire isolated sequence (fi1067 to ›193) is
in exact agreement with a human genomic clone deposited in
GenBank under accession no. AC093416. It is also identical to a
short TOP2B proximal promoter sequence (fi70 to ›193)
deposited by Ng et al. [25] (accession no. U65315), except that a
CG is noted as GC at ›160 to ›161.
For initial characterization of TOP2B promoter activity, the
1.3 kb fragment upstream of the start codon (fi1067 to ›193)
was subcloned into a promoterless luciferase reporter plasmid
such that it was contiguous with the start codon of the luciferase
coding region. This construct was transiently transfected into
HeLa cells, and when assayed for luciferase activity was found to
possess transcriptional activity comparable with that of control
reporter plasmids driven by a simian virus (SV) 40 promoter
(pGL3-control).
Comparison of TOP2B and TOP2A promoter activities
The TOP2B promoter activity was then compared with that
of the TOP2A promoter, which is known to exhibit a moderate
degree of cell-cycle-dependent and proliferation-stimulated tran-
scriptional activity [28,29]. Thus TOP2A and TOP2B promoter
reporter constructs (fi620TOP2A-pGL3 and fi1067TOP2B-
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Figure 1 Sequence of the 5«-flanking and untranslated regions of human
TOP2B
The transcriptional start site is denoted as ›1 [25]. Putative transcriptional regulatory elements
identified in this study are shown in bold, as is the ATG translational start codon. Nucleotide
repeats are underlined.
pGL3) were transiently transfected into NIH3T3 cells. Trans-
fected cells were then growth-arrested by serum starvation for
48 h followed by re-stimulation of proliferation by re-addition of
10% serum. Cell lysates were prepared at specified time intervals
and luciferase activity measured (Figure 2A). The cell cycle
status of cells subjected to the same serum starvation and
replenishment procedures was assessed by flow cytometry (Figure
2B). Initial experiments indicated that the transfection procedures
used had no effect on the subsequent growth arrest by serum
deprivation and proliferation upon serum replenishment. As
shown in Figure 2(A), the activity of the TOP2B promoter
construct did not vary appreciably during serum-stimulated
proliferation of NIH3T3 cells for 24 h. In contrast, TOP2A
promoter activity was relatively low in the first 12 h when the




) and significantly increased
2–3-fold from 12 to 24 h when the cells entered the active phase
of cell growth (S›G
#
›M), consistent with previous observations
using a similar experimental system [28,29]. To further compare
the properties of the TOP2A and TOP2B promoters, the effect of
Figure 2 Comparison of TOP2B and TOP2A promoter regulation
(A) Effect of serum re-stimulated growth on TOP2B and TOP2A promoter reporter activities.
NIH3T3 cells were transfected with reporter constructs of the TOP2A promoter (fi620TOP2A-
pGL3) or TOP2B (fi1067TOP2B-pGL3) together with 10 ng of pRL-CMV as an internal control.
Cells were serum-starved for 48 h and then stimulated to proliferate by replacing the medium
with medium containing 10% serum. At the specified time periods, luciferase activities were
measured using the dual luciferase assay system. Values shown are means‡S.E.M. from three
determinations in a single experiment. Similar results were obtained in a second experiment.
RLU, relative luciferase units. (B) Cell-cycle analysis of NIH3T3 cells. Parallel cultures were
subjected to the same growth-arrest/re-stimulation treatments and harvested at specified
intervals for flow cytometry analysis. The percentages of cells in resting (G0›G1) and active
growth (S›G2›M) phases are indicated.
trichostatin A, a histone deacetylase inhibitor which is known to
activate the TOP2A promoter, was also investigated. As demon-
strated previously, we found that TOP2A promoter activity was
markedly stimulated (" 7-fold) by exposure of cells to tricho-
statin A [30,31]. However, the TOP2B promoter reporter con-
struct was stimulated only 2-fold, which is comparable with the
increase observed for the internal control reporter plasmid (pRL-
CMV; results not shown).
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Figure 3 Deletion analysis of the TOP2B promoter
(A) Schematic diagram of fusion constructs of TOP2B promoter sequences linked to luciferase reporter gene used in this study. (B and C) Reporter gene assays of 5«-deletion constructs (B) and
internal deletion constructs (C). HeLa cells were transfected with 300 ng of DNA of the indicated deletion mutants and 30 ng of pRL-TK for normalization of transfection efficiencies and processed
for measurement of luciferase activities 24 h later. Values shown are means‡S.E.M. from three determinations in a single experiment and are expressed relative to the luciferase activity of the
full-length promoter construct, fi1067TOP2B-pGL3. Similar results were obtained in a second independent experiment. RLU, relative luciferase units.
Deletion analysis of the TOP2B promoter
A panel of 5«-serially deleted TOP2B reporter constructs gener-
ated from fi1067TOP2B-pGL3 were then tested in transient
transfection assays to determine the minimal sequence necessary
to drive luciferase expression (Figure 3A). These experiments
showed that deletion up to fi533 did not appreciably affect
TOP2B promoter activity while further deletions resulted in at
least a 50% decrease in activity (Figure 3B). These findings
suggested that the sequence immediately downstream of fi533
contains elements required for maximal TOP2B promoter
activity. Reporter constructs with deletions of several internal
sequences were generated to further define critical regions in the
TOP2B promoter. Deletion of TOP2B sequence between fi555
and fi456 (D2-TOP2B) resulted in a 70% decrease in luciferase
activity, consistent with results with the 5«-serially deleted re-
porter constructs (Figure 3C). A 35% reduction in promoter
activity was observed for the D6-TOP2B construct which was
lacking fi125 to fi37, a region that has a relatively high GC
content. Whether or not this decrease is significant is unknown
and requires further investigation. Other internal deletions had
either no effect on TOP2B promoter activity or decreased it by
less than 20%.
Mutational analysis of GC box and ICBs
Computer-assisted analyses of the region between fi555 and
fi456, shown to be critical for TOP2B promoter activity, were
carried out using the TRANSFAC database and MatInspector
search program (http:}}transfac.gbf.de}TRANSFAC). These
analyses identified multiple putative regulatory elements, in-
cluding a GC box (Sp1-binding site) at fi553 as well as two
ICBs, ICB1 and ICB2, at fi522 and fi490, respectively (Figures 1
and 4). CCAAT boxes are cis-acting elements recognized by
transcription factors such as NF-Y, CCAAT transcription
factor}nuclear factor-1 (CTF}NF-1) and CCAAT}enhancer-
binding protein (C}EBP) [32], whereas GC boxes are
potential binding sites for members of the Sp family of transcrip-
tion factors [33]. To determine whether these sequences contri-
buted to TOP2B promoter activity, mutations were introduced
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Figure 4 Mutational analysis of putative Sp1 and ICB regulatory elements in the TOP2B promoter
HeLa cells were co-transfected with 300 ng of wild-type or mutant fi1067TOP2B-pGL3 reporter construct DNA and 30 ng of pRL-TK and luciferase activities measured 24 h later. Values shown
are means‡S.E.M. from three determinations in a single experiment, and are expressed relative to the luciferase activity of the wild-type fi1067TOP2B-pGL3 construct. Results shown are
representative of three independent experiments. RLU, relative luciferase units.
Figure 5 GMSAs of the GC box sequence in the TOP2B promoter
HeLa cell nuclear extracts (5 lg) and the indicated 32P-labelled oligonucleotides (20 fmol) were incubated in a reaction volume of 20 ll at room temperature and then resolved on a 6% polyacrylamide
gel. Oligonucleotide sequences are shown in Table 1. (A) Competition GMSA in the presence of 100-fold excess of the indicated unlabelled oligonucleotide competitors. (B) Comparison of binding
activities of sequences corresponding to the wild-type and mutated TOP2B GC box. (C) Supershift assays using 1 lg of anti-Sp1 antibody ; 1 lg of non-immune IgG was used as control. Supershifted
complexes are indicated with an arrow.
into the wild-type fi1067TOP2B-pGL3 construct to generate
mutants with specific disruption of the respective elements (Table
1 and Figure 4). The resulting constructs were then transiently
transfected into HeLa cells and dual luciferase activities measured
as before. As shown in Figure 4, one of the most striking changes
resulted from mutations of both ICB1 and ICB2 (m[ICB1.ICB2]).
This double mutation reduced TOP2B promoter luciferase
activity by 70–80%. In contrast, a single mutation of either the
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Figure 6 GMSAs of the ICBs in the TOP2B promoter
HeLa cell nuclear extracts (5 lg) and the indicated 32P-labelled oligonucleotides or PCR-derived probe (TOP2B fi533 to fi475 ; 20 fmol) were incubated in a reaction volume of 20 ll at room
temperature and then resolved on a 6% polyacrylamide gel. Oligonucleotide sequences are shown in Table 1. (A) Competition GMSA in the presence of 100-fold excess of the indicated unlabelled
oligonucleotide competitors. (B) Comparsion of binding activities of sequences corresponding to wild-type and mutated TOP2B ICBs. (C) Supershift assays, using 1 lg of NF-YA monoclonal antibody,
of the indicated oligonucleotides (left-hand panel) or the PCR-derived probe (TOP2B fi553 to –475) with the indicated mutations (right-hand panel). Non-immune IgG (1 lg) was used as control.
Supershifted complexes are indicated by arrows. WT, wild type.
ICB1 or the ICB2 site did not appreciably affect fi1067TOP2B-
pGL3 activity. These findings suggest that each ICB is sufficient
on its own to support TOP2B promoter activity.
Mutation of the GC box at fi553 (Figure 4) or elimination of
this site, as in the fi533TOP2B-pGL3 construct (Figure 3B), led
to a modest (! 20%) decrease in luciferase activity. However,
when the GC box was mutated together with one or other of the
ICBs, a much more pronounced decrease in luciferase activity
was observed. Thus simultaneous mutation of the GC box and
the proximal ICB (m[GC.ICB2]) caused a 50% decrease in
promoter activity (Figure 4), similar to the decrease observed
with the fi498TOP2B-pGL3 5«-deletion construct in which both
the GC box and ICB2 site are eliminated (Figure 3B). The
combination of mutations in the GC box and the ICB1 site
(m[GC.ICB1]) resulted in a further decrease in promoter activity
to 30% of wild-type fi1067TOP2B-pGL3 activity, a level of
activity similar to that observed when both ICB1 and ICB2 were
mutated (m[ICB1.ICB2] ; Figure 4). All of the mutant constructs
above were also tested in a number of additional cell lines,
including MCF-7, HEK-293, CALU-6 and NIH3T3. In all cases,
comparable results were obtained. Thus the m[ICB1.ICB2],
m[GC.ICB1] and m[GC.ICB1.ICB2] mutants were the most
disruptive and conferred only 20–50% promoter activity (results
not shown).
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DNA-protein binding activities at the ICBs and GC box
To determine whether the ICB1, ICB2 and GC box in the
TOP2B promoter are capable of protein binding, GMSAs were
performed with HeLa cell nuclear extracts. As shown in Figure
5(A), an oligonucleotide (fi561 to fi541) containing the putative
GC box of the TOP2B promoter sequence bound proteins with
mobilities similar to those bound to an oligonucleotide containing
a consensus Sp1 sequence. These binding complexes could be
competed with by a 100-fold excess of unlabelled Sp1-binding
sequence oligonucleotide but not by an excess of oligonucleotides
harbouring a mutated Sp1 sequence (TOP2B mGC; Table 1),
which was shown to be defective in protein binding (Figure 5B).
Furthermore, the major complex was completely supershifted by
an Sp1-specific antiserum (Figure 5C). Thus the GC box of the
TOP2B promoter appears to be a binding site for Sp1.
The ICBs at fi522 and fi490 were investigated in a similar
fashion. As shown in Figure 6(A), shifted complexes were
detected using oligonucleotides corresponding to sequence con-
taining the putative ICB1 (fi501 to fi475) or ICB2 (fi533 to
fi507) as the labelled probes and the electrophoretic mobilities
were similar to those detected using a prototypical CCAAT box
sequence, the Y-box found in the MHC class II (MHC II)
promoter [34]. These complexes could also be effectively
abolished by a 100-fold excess of unlabelled oligonucleotides of
the same sequence. However, they were not affected by an excess
of unlabelled oligonucleotides containing a mutated CCAAT
motif (TOP2B mICB1 or TOP2B mICB2; Table 1), which
showed significantly less binding activity (Figure 6B). These
observations indicate that the ICB sequences are the specific
motif conferring the nuclear protein-binding activities. In ad-
dition, the complexes detected could be competed by a 100-fold
excess of oligonucleotide corresponding to the MHC Y-box
(MHC Y) sequence (Figure 6A). Thus the putative ICB1 and
ICB2 sequences of TOP2B behave in a fashion similar to the
MHC Y-box, which is recognized by the NF-Y transcription
factor [34].
To further characterize the protein-binding activity of the
TOP2B ICBs, antiserum raised against subunit A of NF-Y was
included in the binding assays. As shown in Figure 6(C) (left-
hand panel), the binding activity at both ICBs of the TOP2B
promoter reacted with the anti-NF-YA antibody, but not non-
immune IgG, to form a ‘supershifted’ complex in a manner
similar to that observed in control reactions with the MHC Y
probe. PCR-derived probes corresponding to the TOP2B pro-
moter sequence fi533 to fi475 containing both ICB1 and ICB2
were also employed in a GMSA. As shown in Figure 6(C) (right-
hand panel), binding complexes that reacted with the anti-NF-
YA antibody were also detected using this probe. When either
ICB1 or ICB2 was mutated (mICB1 or mICB2), the anti-NF-YA
antibody still detected binding complexes. However, when both
ICBs were disrupted (m[ICB1.ICB2]), no more supershifted
activity was detected, indicating that the double mutant is
defective for NF-Y binding. The ability of ICB2 to bind NF-Y
appears to be somewhat weaker than that of ICB1 (Figure 6C),
but whether or not this difference is significant requires further
investigation.
Effects of expression of dominant-negative NF-YA on TOP2B
promoter activity
To further investigate the role of NF-Y on TOP2B promoter
activity, a cDNA expression vector encoding a dominant-
negative mutant of the A subunit of NF-Y (NF-YA), which
renders endogenous NF-Y unable to bind to a CCAAT box [32],
Figure 7 Effect of dominant-negative NF-YA expression on TOP2B
promoter luciferase activities
(A) HeLa cells were transfected with 200 ng of wild-type fi1067TOP2B-pGL3 reporter DNA
(WT) or ICB mutated reporter DNA m[ICB1.ICB2] together with 100 ng of expression plasmid
DNA for wild-type NF-YA (WT), dominant-negative NF-YA (DN) or control vector without insert
(pSG5). Individual transfections were normalized by co-transfection with pRL-SV40. Results
shown are representative of three independent experiments. Values shown are means‡S.E.M.
from quadruplicate determinations and are expressed relative to the activity of the wild-type
fi1067TOP2B-pGL3 construct. RLU, relative luciferase units. (B) Confirmation of NF-YA
expression by immunoblot analysis of lysates prepared from transfected HeLa cells.
or a cDNA encoding the wild-type NF-YA was co-transfected
with wild-type and mutant fi1067TOP2B-pGL3 plasmids into
HeLa cells and promoter activity assayed 24 h later (Figure 7).
Results were expressed relative to the activity observed in
independent co-transfections of the empty vector (pSG5) with
the fi1067TOP2B-pGL3 construct (Figure 7A). The results
show that ectopic co-expression of dominant-negative NF-YA
significantly reduced wild-type fi1067TOP2B-pGL3 promoter
activity by approx. 40% whereas co-expression of wild-type NF-
YA had no effect. As shown in Figure 7(B), both the dominant-
negative and wild-type NF-YA were expressed in the transfected
HeLa cells at comparable levels. To confirm that the effect of
dominant-negative NF-YA on TOP2B promoter activity was
due to specific inhibition of NF-Y binding to the ICBs, co-
transfection experiments were also performed using the
fi1067TOP2B-pGL3 construct with both ICBs (m[ICB1.ICB2])
disrupted. In these experiments, dominant-negative NF-YA had
no effect on the luciferase activity of the mutated TOP2B
reporter construct. The dominant-negative NF-YA also had no
effect on promoter activity driven by the SV40 promoter, which
has no CCAAT box (e.g. pRL-SV40 or pGL3-control), or on the
background activity of pGL3-Basic (results not shown).
DISCUSSION
As a first step towards better understanding of the regulation of
human topo IIb expression, we cloned and sequenced the 1.3 kb
5«-flanking region of the TOP2B gene. This TOP2B promoter
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region is very GC-rich and contains clustered CpG or GpC
dinucleotides with features characteristic of a CpG island that
represent potential sites for methylation. Several short nucleotide
repeats were also identified, but whether or not any of these
features play a role in TOP2B gene regulation remains to be
determined. Thus these findings add to our previous knowledge
of the intron}exon organization of the TOP2B gene [5] and the
partial sequence of its promoter [25].
We next analysed the ability of the TOP2B fragment from
fi1067 to ›193 to drive expression of a luciferase reporter gene.
Initially, we compared the properties of the TOP2B promoter
with the relatively well characterized TOP2A proximal pro-
moter [27]. In contrast to TOP2A, we found that the TOP2B
promoter activity was less dependent on cell-proliferation status.
These findings are consistent with previous studies comparing
the relative expression levels of the two isozymes. In addition,
unlike the TOP2A promoter [31], the TOP2B promoter was not
significantly activated by exposure to an inhibitor of histone
deacetylation (C. N. Lok and S. P. C. Cole, unpublished work).
These results confirm that a fundamental difference exists between
the transcriptional regulation of these two genes.
By deletion analysis, we identified a region in the TOP2B
promoter between fi533 and fi481 that appears responsible for
approx. 80% of promoter activity. By introducing specific
mutations into the putative regulatory elements, two ICBs were
identified that are critical for TOP2B promoter activity. DNA–
protein-binding assays clearly demonstrated that these two
putative ICBs bind nuclear factors. CCAAT boxes are found in
the regulatory region of 30% of genes, including those which are
so-called housekeeping genes as well as inducible and cell-cycle-
regulated genes [32]. The role of CCAAT boxes as cis-acting
promoter elements depends on their ability to interact with a
variety of transcription factors. The most prevalent of these is
NF-Y, a ubiquitously expressed heterotrimeric transcription
factor composed of three subunits (NF-YA, NF-YB and NF-
YC) [32]. All three subunits are necessary for constitution of a
functional binding complex to the CCAAT box. Using specific
NF-Y antisera in GMSAs, the ICBs of TOP2B were shown to
bind NF-Y. Our observations using a dominant-negative form of
NF-Y (A subunit) with mutations in the DNA-binding domain,
previously demonstrated to abolish the interaction of NF-Y with
CCAAT boxes [32], further confirm that NF-Y interacts with the
TOP2B ICBs and is involved in TOP2B promoter activity.
An interesting finding of our study is the loss of TOP2B
promoter activity upon simultaneous disruption of the two ICBs
while mutation of a single ICB had little effect. These results
suggest that each ICB by itself is sufficient to support TOP2B
promoter activity. Multiple CCAAT boxes are found in a number
of promoters and their spacing is often variable. The centre-to-
centre distance between the two ICBs of the TOP2B promoter is
30 bp, which is very close to three multiples of a helical turn of
DNA (10.4 bp) [35]. This suggests that protein factors such as
NF-Y that bind to the two ICBs are likely to be situated on the
same side of the helix and are thus located in very close proximity
to one another in the TOP2B promoter. The similar spatial
relationships of the DNA–protein interaction at the two ICBs
may explain, at least in part, our observation that the two
ICBs can be compensatory for one another with respect to their
contribution to TOP2B promoter activity when either one is
mutated. A similar redundancy of functional ICBs has also been
found in the promoter regions of genes encoding human cyclin
B1 and cdc25C [36,37].
The major protein bound to the TOP2B ICBs was identified
as NF-Y. Although extensively studied, the mechanism by which
NF-Y regulates gene expression is still not completely under-
stood. However, one widely recognized property of NF-Y is its
ability to induce distortion of the double helix upon binding to
DNA in itro, thereby influencing the DNA–protein interactions
for gene transcription and hence serving as a ‘promoter
organizer ’ [32]. In the TOP2B promoter, the GC box}Sp1 site is
located in close proximity to ICB2 and we have shown that Sp1
can bind to this site. We have also shown that mutation of this
site, together with the mutation of either one of the ICBs, causes
a significant loss of TOP2B promoter activity. These observations
suggest that a functional synergy may exist between the ICBs and
the GC box in the TOP2B promoter. Such a functional co-
operation between NF-Y and Sp1 has previously been shown to
be essential for the transcriptional activity of promoters of a
number of genes, including the human MHC II-associated
invariant chain (Ii) [38], human and rat fatty acid synthase (FAS)
[39], human cathepsin L [40] and human P-glycoprotein
(ABCB1}MDR1) [41]. In all cases, the Sp1- and NF-Y-binding
sites are located in close proximity to each other in the promoter
regions of these genes. Co-operation may occur in several
different ways. Thus it has been demonstrated that NF-Y and
Sp1 bind co-operatively to the FAS promoter [39]. In addition,
interactions of Sp1 and NF-Y with the p300 co-activator [42,43],
and a direct physical association of NF-Y and Sp1 [44], may also
explain such co-operativity.
In summary, our results indicate that the binding sites for
NF-Y and Sp1 are critical for TOP2B transcription and thus
TOP2B expression may be modulated by the levels or activities
of these transcription factors. Although NF-Y and Sp factors are
considered to be ubiquitously expressed, their levels of expression
or activities still vary depending on cell type and stage of cell
growth and differentiation [32,33], as does TOP2B expression
[11,12]. In this regard, it is of interest that TOP2B mRNA is not
detectable in skeletal muscle [11] and NF-Y is not expressed in
postmitotic differentiated skeletal muscle cells because of a
deficiency of the A subunit [37]. Whether or not a broader
correlation exists between the expression of NF-Y (and Sp1) and
TOP2B expression in normal and}or malignant cells remains to
be determined.
The TOP2A promoter also contains functional ICBs and GC
boxes and the regulation of TOP2A promoter activity by these
elements is known to be complex. All five ICBs in the TOP2A
promoter have been shown to interact with nuclear factors,
including NF-Y [28,30,45,46] as well as a novel CCAAT-box-
binding factor, ICBP90 [47]. Interestingly, both stimulatory and
repressive roles of the individual ICBs in basal, cell-proliferation-
dependent, stress-regulated and drug-resistance-associated
TOP2A promoter activity have been reported in various cellular
backgrounds [28,30,46,48–50]. CCAAT boxes, through their
interaction with NF-Y or other related factors, have also been
shown to play a role in the transcriptional regulation of a
number of cell-cycle-regulated genes, including TOP2A, that
contain a bipartite motif, a so-called cell-cycle-dependent element
(CDE) and a cell-cycle genes homology region (CHR) [51].
However, no similar motif is found in the TOP2B promoter.
Whether this difference accounts for the differential regulation of
TOP2A and TOP2B during cell growth requires further investi-
gation. It is also likely that differences in the organization of the
Sp1- and NF-Y-binding sites in these two promoters are im-
portant as well [52]. Finally, in view of the functional significance
of the ICBs in the regulatory regions of both TOP2 isoforms, it
will be of interest to determine whether the emerging class of
DNA-binding anticancer compounds that can target CCAAT
boxes (or a structurally similar motif ) can affect expression of
TOP2A and TOP2B and hence drug sensitivity of malignant cells
[53].
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